Regeneron Pharmaceuticals (REGN) : Investors lapped up stocks on upticks to the tune of $73.95 million in the Tuesdays trading session. The trading value on downticks was comparatively at $70.49 million and the uptick to downtick ratio of 1.05 indicates continuous buying by the bulls. The net money flow into the stock was $3.46 million. Upticks saw transactions worth $13.05 clearly indicating buying by large investors. The total money flow for block trades stood at $13.05 million, which is a positive for the stock in the long-term. Regeneron Pharmaceuticals (REGN) fell $6.99 during the day at $368.75, a drop of -1.86% over the previous days close. However, for the week, the stock is -2.54%, compared to the previous week.
The company Insiders own 10.4% of Regeneron Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -2.47% . Institutional Investors own 75.16% of Regeneron Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -3.67%. In an insider trading activity, Ryan Arthur F, director of Regeneron Pharmaceuticals Inc, unloaded 1,000 shares at an average price of $396.64 on May 24, 2016. The total amount of the transaction was worth $396,640, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Shares of Regeneron Pharmaceuticals, Inc. appreciated by 2.54% during the last five trading days but lost 0.88% on a 4-week basis. Regeneron Pharmaceuticals, Inc. has dropped 9.64% during the last 3-month period . Year-to-Date the stock performance stands at -32.07%.
Regeneron Pharmaceuticals (NASDAQ:REGN): On Tuesdays trading session , Opening price of the stock was $377 with an intraday high of $379.45. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $368.38. However, the stock managed to close at $368.75, a loss of 1.86% for the day. On the previous day, the stock had closed at $375.74. The total traded volume of the day was 741,481 shares.
Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.